- NeurAxis (NRXS, Financial) to release Q1 2025 financial results before market opens on May 12, 2025.
- A conference call to discuss the results is scheduled for May 12, 2025, at 9:00 a.m. ET.
- NRXS focuses on neuromodulation therapies, with the IB-Stim™ therapy being FDA cleared for IBS-related abdominal pain in adolescents.
NeurAxis, Inc. (NRXS), a medical technology company, will announce its first quarter 2025 financial results on Monday, May 12, 2025, prior to the market opening. The financial results will cover the period ending March 31, 2025.
The company has scheduled a conference call for the same day at 9:00 a.m. Eastern Time to review the financial results. Interested parties can access the call through a live webcast available in the Investor Relations section of the company's website. Questions can be submitted via the webcast portal or sent to [email protected].
NeurAxis is known for its focus on commercializing neuromodulation therapies aimed at treating chronic and debilitating conditions in both children and adults. Its IB-Stim™ therapy, using proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, is FDA approved for treating functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents aged 8-21 years. The company is conducting additional clinical trials for PENFS across various pediatric and adult conditions with significant unmet healthcare needs.
